Literature DB >> 22390719

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

Thomas Prébet, Steven D Gore, Sylvain Thépot, Benjamin Esterni, Bruno Quesnel, Odile Beyne Rauzy, François Dreyfus, Claude Gardin, Pierre Fenaux, Norbert Vey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22390719      PMCID： PMC3768115          DOI： 10.1111/j.1365-2141.2012.09076.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

Authors:  Steven D Gore; Stephen Baylin; Elizabeth Sugar; Hetty Carraway; Carole B Miller; Michael Carducci; Michael Grever; Oliver Galm; Tianna Dauses; Judith E Karp; Michelle A Rudek; Ming Zhao; B Douglas Smith; Jasper Manning; Anchalee Jiemjit; George Dover; Abbie Mays; James Zwiebel; Anthony Murgo; Li-Jun Weng; James G Herman
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

2.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

3.  Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.

Authors:  Celeste Bello; Daohai Yu; Rami S Komrokji; Weiwei Zhu; Gene A Wetzstein; Alan F List; Jeffrey E Lancet
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

4.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

Authors:  Thomas Prébet; Steven D Gore; Benjamin Esterni; Claude Gardin; Raphael Itzykson; Sylvain Thepot; François Dreyfus; Odile Beyne Rauzy; Christian Recher; Lionel Adès; Bruno Quesnel; C L Beach; Pierre Fenaux; Norbert Vey
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

5.  Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Authors:  Raphael Itzykson; Sylvain Thépot; Bruno Quesnel; Francois Dreyfus; Odile Beyne-Rauzy; Pascal Turlure; Norbert Vey; Christian Recher; Caroline Dartigeas; Laurence Legros; Jacques Delaunay; Célia Salanoubat; Sorin Visanica; Aspasia Stamatoullas; Francoise Isnard; Anne Marfaing-Koka; Stephane de Botton; Youcef Chelghoum; Anne-Laure Taksin; Isabelle Plantier; Shanti Ame; Simone Boehrer; Claude Gardin; C L Beach; Lionel Adès; Pierre Fenaux
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

Authors:  Ying Jiang; Andrew Dunbar; Lukasz P Gondek; Sanjay Mohan; Manjot Rataul; Christine O'Keefe; Mikkael Sekeres; Yogen Saunthararajah; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2008-10-02       Impact factor: 22.113

Review 9.  Myelodysplastic syndromes.

Authors:  Stephen D Nimer
Journal:  Blood       Date:  2008-05-15       Impact factor: 22.113

10.  Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

Authors:  Tamer E Fandy; James G Herman; Patrick Kerns; Anchalee Jiemjit; Elizabeth A Sugar; Si-Ho Choi; Allen S Yang; Timothy Aucott; Tianna Dauses; Rosalie Odchimar-Reissig; Jonathan Licht; Melanie J McConnell; Chris Nasrallah; Marianne K H Kim; Weijia Zhang; Yezou Sun; Anthony Murgo; Igor Espinoza-Delgado; Katharine Oteiza; Ibitayo Owoeye; Lewis R Silverman; Steven D Gore; Hetty E Carraway
Journal:  Blood       Date:  2009-06-22       Impact factor: 22.113
  10 in total
  21 in total

1.  Concise drug review: azacitidine and decitabine.

Authors:  Ellen J B Derissen; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2013-05-13

2.  Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.

Authors:  Pragya Srivastava; Benjamin E Paluch; Junko Matsuzaki; Smitha R James; Golda Collamat-Lai; Julia Karbach; Michael J Nemeth; Pietro Taverna; Adam R Karpf; Elizabeth A Griffiths
Journal:  Leuk Res       Date:  2014-09-10       Impact factor: 3.156

3.  BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

Authors:  Tsila Zuckerman; Ron Ram; Luiza Akria; Maya Koren-Michowitz; Ron Hoffman; Israel Henig; Noa Lavi; Yishai Ofran; Netanel A Horowitz; Olga Nudelman; Sigal Tavor; Shay Yeganeh; Stela Gengrinovitch; Liat Flaishon; Shoshi Tessler; Ruth Ben Yakar; Jacob M Rowe
Journal:  Blood Adv       Date:  2019-11-26

Review 4.  Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Mohamed A Kharfan-Dabaja; Rami S Komrokji
Journal:  Curr Opin Hematol       Date:  2014-03       Impact factor: 3.284

5.  Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.

Authors:  P Boddu; J Jorgensen; H Kantarjian; G Borthakur; T Kadia; N Daver; Y Alvarado; N Pemmaraju; P Bose; K Naqvi; M Yilmaz; S Pierce; M Brandt; C D DiNardo; E J Jabbour; M Konopleva; G Garcia-Manero; J Cortes; F Ravandi
Journal:  Leukemia       Date:  2017-09-18       Impact factor: 11.528

6.  Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Authors:  Prajwal Boddu; Hagop M Kantarjian; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Elias Jabbour; Gautam Borthakur; Marina Konopleva; Kapil N Bhalla; Naval Daver; Courtney D DiNardo; Christopher B Benton; Koichi Takahashi; Zeev Estrov; Sherry R Pierce; Michael Andreeff; Jorge E Cortes; Tapan M Kadia
Journal:  Blood Adv       Date:  2017-07-19

7.  Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.

Authors:  Chetasi Talati; Aaron D Goldberg; Amanda Przespolewski; Onyee Chan; Najla Al Ali; Jongphil Kim; Chris Famulare; David Sallman; Eric Padron; Andrew Kuykendall; Jeffrey E Lancet; Eunice Wang; Martin S Tallman; Rami Komrokji; Kendra Sweet
Journal:  Leuk Res       Date:  2020-05-01       Impact factor: 3.156

Review 8.  How and when to decide between epigenetic therapy and chemotherapy in patients with AML.

Authors:  Hervé Dombret; Raphael Itzykson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

9.  Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.

Authors:  Salih Subari; Firas Baidoun; Muhanad Hreh; Mrinal Patnaik; Shahrukh Hashmi; Michelle Elliott; William Hogan; Mark Litzow; Aref Al-Kali
Journal:  Int J Hematol       Date:  2016-01-18       Impact factor: 2.490

10.  Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.

Authors:  Thomas Prebet; Pierre Fenaux; Norbert Vey
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.